Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

PURPOSE: We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. PATIENTS AND METHODS: In this open label phase II study (NCT00253630), patients with relapsed/refra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kirschbaum, Mark, Frankel, Paul, Popplewell, Leslie, Zain, Jasmine, Delioukina, Maria, Pullarkat, Vinod, Matsuoka, Deron, Pulone, Bernadette, Rotter, Arnold J., Espinoza-Delgado, Igor, Nademanee, Auayporn, Forman, Stephen J., Gandara, David, Newman, Edward
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2011
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083875/
https://ncbi.nlm.nih.gov/pubmed/21300924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.1398
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge